| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.3 | 2e-10 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.19 | 2e-09 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | 0.26 | 4e-08 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | 0.15 | 2e-06 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.16 | 4e-06 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.15 | 8e-06 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | 0.22 | 1e-05 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.19 | 2e-05 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-05 |